Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1990 1
1991 3
1992 4
1993 3
1998 2
2000 4
2001 1
2002 1
2003 1
2004 1
2005 2
2006 4
2007 1
2008 2
2010 3
2012 1
2013 3
2014 4
2015 6
2016 1
2017 2
2018 3
2019 1
2020 3
2021 3
2022 6
2023 1
2024 2
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

64 results

Results by year

Filters applied: . Clear all
Page 1
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.
Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P, Porta C, George S, Powles T, Donskov F, Neiman V, Kollmannsberger CK, Salman P, Gurney H, Hawkins R, Ravaud A, Grimm MO, Bracarda S, Barrios CH, Tomita Y, Castellano D, Rini BI, Chen AC, Mekan S, McHenry MB, Wind-Rotolo M, Doan J, Sharma P, Hammers HJ, Escudier B; CheckMate 214 Investigators. Motzer RJ, et al. N Engl J Med. 2018 Apr 5;378(14):1277-1290. doi: 10.1056/NEJMoa1712126. Epub 2018 Mar 21. N Engl J Med. 2018. PMID: 29562145 Free PMC article. Clinical Trial.
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.
Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Choueiri TK, Gurney H, Donskov F, Bono P, Wagstaff J, Gauler TC, Ueda T, Tomita Y, Schutz FA, Kollmannsberger C, Larkin J, Ravaud A, Simon JS, Xu LA, Waxman IM, Sharma P; CheckMate 025 Investigators. Motzer RJ, et al. N Engl J Med. 2015 Nov 5;373(19):1803-13. doi: 10.1056/NEJMoa1510665. Epub 2015 Sep 25. N Engl J Med. 2015. PMID: 26406148 Free PMC article. Clinical Trial.
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.
Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F, Hammers H, Hutson TE, Lee JL, Peltola K, Roth BJ, Bjarnason GA, Géczi L, Keam B, Maroto P, Heng DY, Schmidinger M, Kantoff PW, Borgman-Hagey A, Hessel C, Scheffold C, Schwab GM, Tannir NM, Motzer RJ; METEOR Investigators. Choueiri TK, et al. N Engl J Med. 2015 Nov 5;373(19):1814-23. doi: 10.1056/NEJMoa1510016. Epub 2015 Sep 25. N Engl J Med. 2015. PMID: 26406150 Free PMC article. Clinical Trial.
Randomized Phase II Study of Nivolumab With or Without Ipilimumab Combined With Stereotactic Body Radiotherapy for Refractory Metastatic Pancreatic Cancer (CheckPAC).
Chen IM, Johansen JS, Theile S, Hjaltelin JX, Novitski SI, Brunak S, Hasselby JP, Willemoe GL, Lorentzen T, Madsen K, Jensen BV, Wilken EE, Geertsen P, Behrens C, Nolsoe C, Hermann KL, Svane IM, Nielsen D. Chen IM, et al. Among authors: geertsen p. J Clin Oncol. 2022 Sep 20;40(27):3180-3189. doi: 10.1200/JCO.21.02511. Epub 2022 Apr 27. J Clin Oncol. 2022. PMID: 35476508 Clinical Trial.
Phase 2 study of ipilimumab, nivolumab, and tocilizumab combined with stereotactic body radiotherapy in patients with refractory pancreatic cancer (TRIPLE-R).
Chen IM, Donia M, Chamberlain CA, Jensen AWP, Draghi A, Theile S, Madsen K, Hasselby JP, Toxværd A, Høgdall E, Lorentzen T, Wilken EE, Geertsen P, Svane IM, Johansen JS, Nielsen D. Chen IM, et al. Among authors: geertsen p. Eur J Cancer. 2023 Feb;180:125-133. doi: 10.1016/j.ejca.2022.11.035. Epub 2022 Dec 10. Eur J Cancer. 2023. PMID: 36592507 Free article. Clinical Trial.
Nivolumab with or without Ipilimumab Combined with Stereotactic Body Radiotherapy in Patients with Metastatic Biliary Tract Cancer: A Randomized Phase 2 Study.
Markussen A, Johansen JS, Larsen FO, Theile S, Hasselby JP, Willemoe GL, Lorentzen T, Madsen K, Høgdall E, Poulsen TS, Wilken EE, Geertsen P, Behrens CP, Svane IM, Nielsen D, Chen IM. Markussen A, et al. Among authors: geertsen p. Clin Cancer Res. 2024 Aug 15;30(16):3428-3437. doi: 10.1158/1078-0432.CCR-24-0286. Clin Cancer Res. 2024. PMID: 38874506 Clinical Trial.
The value of gynecologic cancer follow-up: evidence-based ignorance?
Lajer H, Jensen MB, Kilsmark J, Albæk J, Svane D, Mirza MR, Geertsen PF, Reerman D, Hansen K, Milter MC, Mogensen O. Lajer H, et al. Among authors: geertsen pf. Int J Gynecol Cancer. 2010 Nov;20(8):1307-20. doi: 10.1111/IGC.0b013e3181f3bee0. Int J Gynecol Cancer. 2010. PMID: 21051970 Free article. Review.
KRAS and BRAF mutations in anal carcinoma.
Serup-Hansen E, Linnemann D, Høgdall E, Geertsen PF, Havsteen H. Serup-Hansen E, et al. Among authors: geertsen pf. APMIS. 2015 Jan;123(1):53-9. doi: 10.1111/apm.12306. Epub 2014 Sep 22. APMIS. 2015. PMID: 25244542
[Interleukin-2 based immunotherapy of cancer].
Geertsen PF, Hermann GG, Claësson MH, Steven K, Zeuthen J, von der Maase H. Geertsen PF, et al. Ugeskr Laeger. 1990 Nov 19;152(47):3513-7. Ugeskr Laeger. 1990. PMID: 2256204 Review. Danish.
64 results